Blossomhill Says FDA Grants Fast Track Designation To BH-30643 For Treatment Of Adult Patients With Advanced Or Metastatic EGFR C797S-Positive NSCLC After Prior Treatment With Third-Gen EGFR Tyrosine Kinase Inhibitor
BlossomHill Therapeutics, Inc. (NASDAQ:BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of
Blossomhill's new cancer medicine just got a special fast-track approval from the FDA, which means the government thinks it could help patients and will review it faster than normal. This shows the company is making progress on real medicines, so investors will watch to see if the drug works well in patient tests.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.